Inrebic Side Effects

Generic name: fedratinib

Medically reviewed by Drugs.com. Last updated on May 19, 2024.

Note: This document provides detailed information about Inrebic Side Effects associated with fedratinib. Some dosage forms listed on this page may not apply specifically to the brand name Inrebic.

Applies to fedratinib: oral capsule.

Important warnings This medicine can cause some serious health issues

Oral route (capsule)

Warning: Encephalopathy including Wernicke'sSerious and fatal encephalopathy, including Wernicke’s, has occurred in patients treated with fedratinib.

Wernicke’s encephalopathy is a neurologic emergency.

Assess thiamine levels in all patients prior to starting fedratinib, periodically during treatment, and as clinically indicated.

Do not start fedratinib in patients with thiamine deficiency; replete thiamine prior to treatment initiation.

If encephalopathy is suspected, immediately discontinue fedratinib and initiate parenteral thiamine.

Monitor until symptoms resolve or improve and thiamine levels normalize.

Serious side effects of Inrebic

Along with its needed effects, fedratinib (the active ingredient contained in Inrebic) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur while taking fedratinib:

More common side effects

• black, tarry stools
• bleeding gums
• blood in the urine or stools
• chills
• cough
• fever
• lower back or side pain
• painful or difficult urination
• pale skin
• pinpoint red spots on the skin
• sore throat
• trouble breathing with exertion
• ulcers, sores, or white spots in the mouth
• unusual bleeding or bruising
• unusual tiredness or weakness

Less common side effects

• bladder pain
• cloudy urine
• confusion
• difficult, burning, or painful urination
• drowsiness
• frequent urge to urinate
• lower back or side pain
• shakiness and unsteady walk
• trouble remembering
• uncontrolled eye movements
• unsteadiness, trembling, or other problems with muscle control or coordination

Incidence not known

• anxiety
• chest pain
• dizziness or lightheadedness
• fainting
• fast heartbeat
• general feeling of illness
• pain, redness, or swelling in arm or leg
• pains in the chest, groin, or legs, especially calves of legs
• persistent non-healing sore
• pink growth
• reddish patch or irritated area
• shiny bump
• sudden loss of coordination
• sudden onset of slurred speech
• sudden vision changes
• swollen glands
• weight loss
• white, yellow or waxy scar-like area
• yellow skin and eyes

Other side effects of Inrebic

Some side effects of fedratinib may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common side effects

• bone pain
• diarrhea
• headache
• lack or loss of strength
• muscle spasms
• nausea
• pain in the arms or legs
• vomiting
• weight gain

For healthcare professionals

Applies to fedratinib: oral capsule.

General adverse events

The most commonly reported side effects included anemia, diarrhea, nausea, and increased blood creatinine.^[Ref]

Cardiovascular

• Common (1% to 10%): Cardiac failure, cardiogenic shock, hypertension, myocardial ischemia
• Frequency not reported: Major adverse cardiac events (MACE), thrombosis^[Ref]

Gastrointestinal

• Very common (10% or more): Diarrhea (up to 67.5%), nausea (up to 62%), vomiting (up to 44.8%), increased lipase (up to 35%), increased amylase (up to 24%)
• Common (1% to 10%): Constipation, dyspepsia
• Frequency not reported: Gastrointestinal toxicity^[Ref]

Genitourinary

• Common (1% to 10%): Dysuria, urinary tract infection^[Ref]

Hematologic

• Very common (10% or more): Anemia (up to 99%), thrombocytopenia (up to 68.5%), neutropenia (up to 23%)
• Common (1% to 10%): Bleeding^[Ref]

Hepatic

• Very common (10% or more): Elevated ALT (up to 43%), elevated AST (up to 40%)
• Frequency not reported: Liver toxicity^[Ref]

Metabolic

• Very common (10% or more): Hyponatremia (up to 26%)
• Common (1% to 10%): Weight gain^[Ref]

Musculoskeletal

• Very common (10% or more): Muscle spasms (up to 12%), extremity pain (up to 10%)
• Common (1% to 10%): Bone pain^[Ref]

Nervous system

• Common (1% to 10%): Dizziness, headache, Wernicke's encephalopathy
• Frequency not reported: Encephalopathy^[Ref]

Other

• Very common (10% or more): Asthenia/fatigue (up to 19%)^[Ref]

Renal

• Very common (10% or more): Blood creatinine increased (up to 59%)
• Frequency not reported: Cystitis^[Ref]

Oncologic

• Frequency not reported: Secondary malignancies^[Ref]

Frequently asked questions

• What are JAK inhibitors and how do they work?
• Which JAK inhibitors are approved in the U.S?

Further information

Inrebic side effects can vary depending on the individual. Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Note: Medication side effects may be underreported. If you are experiencing side effects that are not listed, submit a report to the FDA by following this guide.

Medical Disclaimer